Related Experiment Video

Updated: Dec 8, 2025

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

3.8K

Recent advances in the role of sphingosine 1-phosphate in cancer

Nigel J Pyne1, Susan Pyne1

  • 1Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.

FEBS Letters
|September 24, 2020
PubMed

Insights

Sphingosine 1-phosphate (S1P) signaling is crucial in cancer, influencing hallmarks like transformation. Targeting S1P pathways offers new precision medicine strategies to combat aggressive and drug-resistant cancers.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in cell signaling.
  • S1P interacts with G protein-coupled receptors (S1P1-5) and intracellular targets.
  • S1P plays a significant role in cancer development and progression.

Purpose of the Study:

  • To review recent developments in S1P signaling in cancer.
  • To explore the prognostic implications of S1P receptors and enzymes.
  • To identify novel therapeutic strategies targeting S1P in cancer treatment.

Main Methods:

  • Literature review of recent developments in S1P signaling and cancer.
  • Analysis of prognostic indications of S1P receptors and enzymes.
  • Evaluation of therapeutic approaches targeting S1P pathways.

Main Results:

  • S1P signaling is implicated in cancer hallmarks, including transformation and replicative immortality.
  • S1P receptors and enzymes have prognostic significance for disease-specific survival and recurrence.
  • Targeting S1P can prevent neovascularization, revert drug-resistant cancers, and induce cytotoxicity.

Conclusions:

  • Sphingosine 1-phosphate signaling is a promising target for precision medicine in stratified cancer patients.
  • Isoform-specific inhibitors of sphingosine kinases are under development for cancer treatment.
  • Targeting S1P pathways offers potential for novel therapeutic interventions in oncology.
Keywords:
EMTSTATYAPcancer stem cellsmetastasissphingosine 1-phosphatesphingosine 1-phosphate lyasesphingosine 1-phosphate phosphatasesphingosine 1-phosphate receptorssphingosine kinase

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.0K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.7K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K